Maria Chiara Finazzi

8PUBLICATIONS
34CO-AUTHORS
HaematologyGene and molecular therapyRespiratory diseasesCell physiologyNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 24, 2025
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

Alexandros Rampotas, Jose Maria Aspa-Cilleruelo, Linda Koster

|Oct 21, 2025
The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

Maria Chiara Finazzi, Silvia Salmoiraghi, Francesca Valsecchi

|Jun 06, 2025
The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

Margherita Maffioli, Barbara Mora, Alessandra Iurlo

|Feb 03, 2025
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.

Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio

|May 21, 2024
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.

Marta Castelli, Maria Caterina Micò, Anna Grassi

|Mar 14, 2024
JAK inhibitor treatment-resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?

Maria Chiara Finazzi, Ayalew Tefferi, Alessandro Rambaldi

Pageof 2

Frequent Collaborators

5 joint publications

Alessandro Rambaldi

3 joint publications

Federico Lussana

1 joint publications

Paola Guglielmelli

1 joint publications

Alessandra Carobbio